NCT02399462撤回4 期
Acthar for Treatment of Post-transplant FSGS
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- number of patients with proteinuria
研究概览
简要总结
This is an open label safety and feasibility trial using Acthar® in addition to center-specific standard therapy including plasma exchange, for treatment of post transplant recurrent FSGS and post transplant recurrent idiopathic membranous nephropathy. Subjects will receive Acthar® 40 units subcutaneously (SC) twice weekly for two weeks then 80 units SC twice weekly for 24 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years
- •Proteinuria > 1 g/d by urine protein/creatinine ratio (UP/C) or 24 hour urine collection
- •If treated with an angiotensin-converting-enzyme inhibitor (ACEi) or Angiotensin II receptor blockers (ARB), must be on a stable dose for at least 2 weeks prior to enrollment
- •Newly diagnosed recurrent focal and segmental glomerulosclerosis (FSGS), or current/previous treatment of recurrent FSGS with no evidence of at least a partial response as defined by one or more of the following:
- •Recurrent FSGS confirmed by renal transplant biopsy (FSGS on light microscopy and/or foot process effacement on electron microscopy), with FSGS as the primary disease confirmed by native renal biopsy prior to transplant
- •FSGS confirmed by renal transplant biopsy (FSGS on light microscopy and/or foot process effacement on electron microscopy), within 18 months post transplant
- •Patients at any time period post transplant with an established diagnosis of recurrent FSGS in the first 18 months post transplant who did not respond to conventional therapy as defined by persistent proteinuria of > 3 g/d by UP/C or 24 hour urine collection
排除标准
- •Lactation, pregnancy or refusal of birth control in women of childbearing potential
- •Infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or parvovirus B-19
- •Malignancy (with the exception of treated and cured basal cell or squamous cell carcinoma)
- •Evidence of diabetic nephropathy, transplant glomerulopathy or other pathologies that could be associated with secondary FSGS on renal transplant biopsy
- •Non-renal organ transplant (with the exception of pancreas transplant)
- •Contraindication to receiving Acthar®
研究组 & 干预措施
Study Drug Arm
Experimental
Acthar SC injections
干预措施: Acthar (Drug)
结局指标
主要结局
number of patients with proteinuria
时间窗: 24 and 52 weeks
partial and complete remission of proteinuria
次要结局
- Graft loss(during study period)
- eGFR change(weeks 4,8,12,16,20 and 24)
研究者
研究点 (1)
Loading locations...
相似试验
终止
4 期
Treatment of Chronic Antibody-mediated Rejection in Kidney Transplant With ActharTransplant GlomerulopathyNCT02546492University of Maryland, Baltimore6
已完成
3 期
Use of Acthar in Patients With FSGS That Will be Undergoing Renal TransplantationFSGSNCT02683889University of Colorado, Denver15
撤回
4 期
ACTHAR GEL in Patients With Membranous (Class V) Lupus NephritisSLE Glomerulonephritis Syndrome, WHO Class VNCT01926054Ohio State University
Unknown
4 期
Efficacy and Safety of H.P. ACTHAR GEL in Adults With Retinal VasculitisUveitis, PosteriorVasculitis RetinalNCT03066869Ocular Immunology and Uveitis Foundation40
已完成
3 期
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft RejectionChronic Obstructive PulmonaryPulmonary Vascular DiseaseCystic FibrosisIdiopathic Pulmonary FibrosisBronchiectasisNCT00105183Neovii Biotech223